FDA Approves Zenocutuzumab-zbco for Advanced, Unresectable or Metastatic Cholangiocarcinoma By Ogkologos - May 20, 2026 254 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for safety and efficacy is based on the findings from the eNRGy study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR FDA Approves Nivolumab for Adjuvant Treatment of Stage IIB/C Melanoma October 26, 2023 Opioid Use Drops Among Cancer Patients at End of Life August 20, 2021 EMA Recommends Extension of Therapeutic Indications for Cabozantinib and Nivolumab March 4, 2021 New on NCI’s Websites for March 2021 March 25, 2021 Load more HOT NEWS EMA Recommends Granting a Conditional Marketing Authorisation for Belantamab Mafodotin Reduction Not Only in Recurrences, but Also in Mortality, Observed for... No Improvement in OS or PFS from Sacituzumab Govitecan Compared with... FDA Approves Mirvetuximab Soravtansine-gynx for FRα-positive, Platinum-resistant Epithelial Ovarian, Fallopian Tube,...
